ENDOCRINOLOGY AND DIABETES OPEN ACCESS (ISSN:2631-374X)

Biography:

Dr. Hassan Shora is a senior researcher at Port-Said university, member of supervising committee of PhD & MSc theses in molecular medicine cooperating with staff of department of biochemistry & molecular biology at faculty of science. He also is the Head of medicine & Director of diabetes center at Ismailia General Hospital and works as a senior lecturer, Egyptian Board of physicians to train medical residents in Ismailia, Egypt. Dr. Shora is awarded Physician Recognition Award of The American Medical Association in 2003-2006 and 2007-2010. He published his first paper in 1984 while he was a second year undergraduate student and published several original research papers thereafter in international journals in role of adiponectin and glycemic control in delaying subclinical atherosclerotic changes in type 1 diabetics, markers of subclinical atherosclerosis in type 1 diabetics, visceral fat and liver size as determinants of subclinical arthrosclerosis in type 1 diabetic adolescents, inflammatory biomarkers of cardio metabolic risk in obese type 2 diabetics, iron binding stores in correlation with cardio metabolic risk in obese type 2 diabetics, hormonal metabolic and radiological markers of subclinicl atherosclerosis in type 1 diabetics and NT ProPNB as a marker of microvascular complications in type 2 diabetes. Dr. Shora is a member of Asian Council of Science Editors and Editor of Clinical Endocrinology and Diabetes, Reports in Endocrine Disorders, SM journal of general medicine, Current Trends in General Practice and is working as editorial board member and peer reviewer for thirty journals worldwide including journals of Diabetes& Diabetes Care.

Research Interests:

Dr. Shora researches interest in molecular diabetic medicine for novel biomarkers to detect early complications of diabetes. Interests: Adiponectin, adipose tissue, obesity, atherosclerosis, diabetic microvascular complications, cardiometabolic risk, novel anti-inflammatory therapies MoAb, for CVD prevention, systems and precision medicine for diabetes management.